Novo Nordisk A/S: People with type 2 diabetes achieve 6% weight loss with liraglutide 3 mg in phase 3a obesity trial

Novo Nordisk A/S: People with type 2 diabetes achieve 6% weight loss with 
liraglutide 3 mg in phase 3a obesity trial 
BAGSVAERD, DENMARK -- (Marketwire) -- 03/18/13 --  
Company announcement No 19 / 2013: 
http://hugin.info/2013/R/1685937/552525.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Novo Nordisk A/S via Thomson Reuters ONE 
[HUG#1685937] 
Further information
Media:
Katrine Sperling
+45 3079 6718
krsp@novonordisk.com 
Ken Inchausti
+1 609 786 8316
kiau@novonordisk.com 
Ambre Morley
+1 609 987 5898
abmo@novonordisk.com 
Investors:
Kasper Roseeuw Poulsen
+45 4442 4303
krop@novonordisk.com 
Frank Daniel Mersebach
+45 4442 0604
fdni@novonordisk.com 
Lars Borup Jacobsen
+45 3075 3479
lbpj@novonordisk.com 
Jannick Lindegaard (US)
+1 609 786 4575
jlis@novonordisk.com
 
 
Press spacebar to pause and continue. Press esc to stop.